Cowen & Co. Keeps Their Buy Rating on Trillium Therapeutics (TRIL)


Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics (NASDAQ: TRIL) today. The company’s shares opened today at $5.05, close to its 52-week low of $4.15.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.5% and a 47.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Currently, the analyst consensus on Trillium Therapeutics is a Moderate Buy with an average price target of $10.

See today’s analyst top recommended stocks >>

Based on Trillium Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.77 million. In comparison, last year the company had a GAAP net loss of $8.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts